Present data from expansion of Phase 1 studies with RP2 and RP3
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Nov 2021
- Due
- 31 Dec 2022
- Delivered
- December 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we look forward to presenting data during 2022 from the expansion of our Phase 1 studies with RP2 and RP3”
What we found
Evidence strength A What the grades mean
The company presented data from Phase 1 expansion studies for both RP2 and RP3 in December 2022, fulfilling the commitment to present data during 2022.
-
A Replimune Group, Inc. 10-Q filed 2023-02-09
“In December 2022, we reported that of 14 patients with uveal melanoma for which sufficient follow-up was available for assessment, 4 patients had achieved a response.” ✓ confirmed on the page
-
A Replimune Group, Inc. 10-Q filed 2023-02-09
“In December 2022, the Company presented data from its Phase 1 trial of RP3 in combination with nivolumab (N=5) in patients with multiple soft tissue sarcomas” ✓ confirmed on the page
Market reaction: the shares moved -11.9% against the S&P 500 over the three sessions around the disclosure (8 Feb 2023 to 13 Feb 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Data from expansion of Phase 1 studies with RP2 and RP3
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-REPL-002640 · Corrections policy